Category: Clinical Trials
Decentralized and hybrid designs promise better access and retention, but ePRO, wearables, and remote monitoring are hard to operationalize.
Decentralized and hybrid trials can widen access and improve retention by bringing visits, data capture, and monitoring to the patient. But operationalizing ePRO, wearables, telemedicine, and home-based assessments — while keeping data clean and compliant — is genuinely difficult. AI and digital-trial platforms help model where decentralization adds value and support remote data capture and monitoring at scale.
Most of a decentralized trial is logistics — eConsent, televisits, home nursing, direct-to-patient supply — and that is platform work, not AI. Where AI specifically earns its place is in the data: cleaning and quality-checking the high-volume streams that wearables and ePRO generate, flagging anomalous or missing device data early, and modeling which visits and assessments in a protocol can safely move off-site in the first place. Design-stage analysis matters more than most teams expect: decentralization applied indiscriminately can add patient burden rather than remove it. Tools that simulate the operational impact of hybrid design choices help target remote elements where they genuinely reduce burden.
Regulatory fit comes first: the platform must support compliant eConsent, data provenance, and audit trails in every geography your trial touches, and requirements differ meaningfully between regions. Then examine data flow — how device and ePRO data reaches your EDC or data repository, who reconciles discrepancies, and what happens when a device fails mid-study. Finally, assess the patient experience honestly: apps and devices exclude some populations. Ask what accessibility accommodations, translated interfaces, and non-digital fallbacks exist, because differential dropout is both an ethical and a statistical problem.
Few sponsors jump straight to fully decentralized designs. The typical path is adding one or two hybrid elements — eConsent or ePRO first, since they are mature and well-precedented — to a conventional trial, building operational experience and site trust before extending to wearables, home visits, and remote monitoring in later studies.
A trial in which some or all activities happen away from a traditional investigative site — consent by video, outcomes reported through an app, samples drawn at home or a local lab, monitoring done remotely. Most real-world implementations are hybrid: a conventional site backbone with selected remote elements.
Major regulators including the FDA and EMA have issued guidance supporting decentralized elements, and many approved medicines already carry evidence from trials with remote components. Acceptance is about fit-for-purpose execution — data integrity, provenance, and patient safety — not about decentralization per se.
They are designed to reduce participation burden, which is a major driver of dropout, and lower burden is a reasonable expectation for many protocols. But the effect depends on the population and design — remote technology can add burden for some patients — so treat retention improvement as a hypothesis to design for, not a guaranteed outcome.
Volume goes up and controlled conditions go away, which is exactly why AI-assisted data review is valuable in this setting: continuous device streams need automated screening for gaps, artifacts, and implausible values, with human review of what gets flagged. Ask vendors to show their data-quality workflow on real study data, not slides.
The European Medicines Agency issued a qualification opinion on PROCOVA, the prognostic covariate adjustment methodology underpinning Unlearn's digital-twin approach, supporting its use to increase statistical efficiency in randomized controlled trials.
Vendor: Unlearn.AI · regulatory filing (European Medicines Agency) · 2022-09-01
Medable launched a partner program to help contract research organizations and technology partners stand up its decentralized and hybrid trial platform faster, with greater control and transparent pricing.
Vendor: Medable · press release (Medable) · 2025-06-10